CTOR Company Profile and Key Details

CTOR has shown mixed momentum, losing -1.87% over the past week and -38.24% over the past quarter, though year-to-date performance is up 5.0%. Short-term trend indicators are bullishly aligned (SMA20 1.09%, SMA50 -3.0%, SMA200 -30.57%). The stock’s 14-day RSI is 49.01 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.07% below its high and over 101.6% above its low. Average 10-day trading volume of 206.05 thousand shares is below the 3-month average of 441.42 thousand, indicating normal recent market interest.

Citius Oncology, Inc. has 78.37 million shares outstanding. The public float is 16.37 million shares, elevated short interest at 2.46% of float. This equals 303.36 thousand shares. The short ratio is 0.84 days. Institutional investors hold 5.71% of the float. Insiders own 86.83%.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Citius Oncology, Inc. generated EPS of -$0.34 over the past year. Five-year average earnings growth is -309.67%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers 440.54% upside. The low target suggests 440.54% downside. The mean target is $6.00. This offers 440.54% upside. Citius Oncology, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended December 23, 2025, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in December 27, 2024.

Citius Oncology, Inc. trades at a P/E ratio of -3.56, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.97 suggesting the stock is closer to book value. The P/FCF stands at -17.38, also below market averages.

Citius Oncology, Inc. (NASDAQ:CTOR) shares are flat 5.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Citius Oncology, Inc. trading at a premium to the broader market with a P/E of -3.56. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.50, suggesting 305.41% upside.

Our AI price prediction model suggests that Citius Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by May 06, 2026, with a range of $0.00 to $0.73. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by February 05, 2027, within a range of $0.00 to $0.70.